Stereotactic Radiation Therapy for Non-Small Cell Lung Cancer

Stereotactic radiation therapy has emerged as a cornerstone in the management of early-stage and locally recurrent non-small cell lung cancer (NSCLC), particularly in patients who are medically inoperable or decline surgery. By delivering highly conformal, ablative doses of radiation in a small number of fractions, stereotactic techniques achieve excellent local tumour control while sparing surrounding healthy lung and critical mediastinal structures. Advances in image guidance, including four-dimensional computed tomography and cone-beam CT, enable precise tumour localisation throughout the respiratory cycle. The introduction of magnetic resonance-guided adaptive therapy allows daily adjustment of treatment plans to account for anatomical changes, further improving the therapeutic window. Globally, this modality has reshaped treatment guidelines for peripheral stage I tumours and is being explored in oligometastatic and central-lesion settings, with ongoing efforts to define safe dose constraints for ultracentral targets and to integrate systemic immunomodulators.

Research from Nature Portfolio

Recent investigations of magnetic resonance-guided adaptive stereotactic therapy for ultracentral lung lesions have demonstrated significant improvements in dose conformity and clinical outcomes. Daily plan adaptation reduced maximal dose to the proximal airways by approximately 5.7 Gy and increased gross tumour prescription coverage by over 7 %, without any grade 3 or higher toxicities. Two-year local control exceeded 92 %, and structure-specific rigid dose accumulation analyses provided new insights into cumulative dose distribution, underscoring the value of adaptive strategies in maximising the therapeutic ratio for challenging central NSCLC lesions.

Stereotactic Radiation Therapy for Non-Small Cell Lung Cancer publication trend

The graph below shows the total number of articles in stereotactic radiation therapy for non-small cell lung cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Stereotactic Ablative Radiotherapy (SABR): A high-precision technique delivering large fractional radiation doses in few sessions to ablate tumour tissue.

Magnetic Resonance-guided Adaptive Radiation Therapy (SMART): A modality using daily MRI imaging to adapt dose distributions in response to anatomical changes.

Planning Target Volume (PTV): The clinical target volume plus margins accounting for patient movement and setup variation.

Proximal Bronchial Tree (PBT): Central airway structures at heightened risk of toxicity when treating ultracentral lung tumours.

Dose-volume Histogram (DVH): A graphical summary of the percentage of a volume receiving defined radiation doses.

References

1. Structure-specific rigid dose accumulation dosimetric analysis of ablative stereotactic MRI-guided adaptive radiation therapy in ultracentral lung lesions. Communications Medicine (2024).
2. Re-irradiation in clinical practice: Results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform. Radiotherapy and Oncology (2023).
3. The HILUS-Trial—a Prospective Nordic Multicenter Phase 2 Study of Ultracentral Lung Tumors Treated With Stereotactic Body Radiotherapy. Journal of Thoracic Oncology (2021).
4. Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiation Oncology (2009).
5. Long-term results of a prospective phase II trial of medically inoperable stage I NSCLC treated with SBRT – the Nordic experience. Acta Oncologica (2015).